Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stake Boosted by Choreo LLC

Choreo LLC raised its holdings in shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) by 12.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 65,002 shares of the company’s stock after purchasing an additional 7,080 shares during the period. Choreo LLC owned about 0.18% of Checkpoint Therapeutics worth $133,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. 180 Wealth Advisors LLC bought a new position in shares of Checkpoint Therapeutics in the 2nd quarter worth about $96,000. Vanguard Group Inc. lifted its position in shares of Checkpoint Therapeutics by 67.4% in the 1st quarter. Vanguard Group Inc. now owns 917,894 shares of the company’s stock worth $1,882,000 after buying an additional 369,586 shares during the last quarter. Lindbrook Capital LLC bought a new position in shares of Checkpoint Therapeutics in the 1st quarter worth about $62,000. B. Riley Wealth Advisors Inc. lifted its position in shares of Checkpoint Therapeutics by 232.3% in the 4th quarter. B. Riley Wealth Advisors Inc. now owns 163,350 shares of the company’s stock worth $374,000 after buying an additional 114,200 shares during the last quarter. Finally, Armistice Capital LLC lifted its position in shares of Checkpoint Therapeutics by 17.5% in the 4th quarter. Armistice Capital LLC now owns 2,426,000 shares of the company’s stock worth $5,556,000 after buying an additional 362,000 shares during the last quarter. Institutional investors own 22.00% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Checkpoint Therapeutics in a research report on Monday, September 16th.

Checkpoint Therapeutics Stock Performance

Checkpoint Therapeutics stock opened at $2.41 on Friday. The company has a market cap of $86.00 million, a P/E ratio of -0.87 and a beta of 1.29. The firm’s 50-day moving average is $2.34 and its 200-day moving average is $2.03. Checkpoint Therapeutics, Inc. has a 1 year low of $1.30 and a 1 year high of $3.62.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.11. The firm had revenue of $0.04 million during the quarter. As a group, sell-side analysts predict that Checkpoint Therapeutics, Inc. will post -0.81 earnings per share for the current year.

Insider Activity at Checkpoint Therapeutics

In related news, CFO William Garrett Gray sold 13,038 shares of Checkpoint Therapeutics stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $2.06, for a total value of $26,858.28. Following the sale, the chief financial officer now directly owns 672,186 shares in the company, valued at approximately $1,384,703.16. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Checkpoint Therapeutics news, CEO James F. Oliviero III sold 24,610 shares of the firm’s stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $2.05, for a total transaction of $50,450.50. Following the transaction, the chief executive officer now owns 1,977,170 shares of the company’s stock, valued at approximately $4,053,198.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO William Garrett Gray sold 13,038 shares of the firm’s stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $2.06, for a total transaction of $26,858.28. Following the transaction, the chief financial officer now directly owns 672,186 shares in the company, valued at approximately $1,384,703.16. The disclosure for this sale can be found here. 2.10% of the stock is currently owned by insiders.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.